ARS Pharmaceuticals, Inc. (SPRY) is a publicly traded company in the Unknown sector. Across all available filings, 19 corporate insiders have executed 224 transactions totaling $127.9M, demonstrating a bearish sentiment with -$25.4M in net insider flow. The most recent transaction on Nov 13, 2025 involved a sale of 21,828 shares valued at $190.1K.
No significant insider buying has been recorded for SPRY in the recent period.
No significant insider selling has been recorded for SPRY in the recent period.
Based on recent SEC filings, insider sentiment for SPRY is bearish with an Insider Alignment Score of 40/100 and a net flow of -$25.4M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ARS Pharmaceuticals, Inc. (SPRY) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 19 insiders are actively trading SPRY stock, having executed 224 transactions in the past 90 days. The most active insider is Capital Management, L.p. Ra (Executive), who has made 4 transactions totaling $36.5M.
Get notified when executives and directors at SPRY file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 13, 2025 | Dorsey Brian | Executive | Sale | 21,828 | $8.71 | $190.1K | |
| Nov 13, 2025 | Dorsey Brian | Executive | Option Exercise | 21,828 | $0.64 | $14.0K | |
| Nov 12, 2025 | Shah Pratik | Executive | Gift | 250,000 | $N/A | $0 | |
| Nov 12, 2025 | Shah Pratik | Executive | Gift | 100,000 | $N/A | $0 | |
| Nov 12, 2025 | Chakma Justin | Executive | Option Exercise | 30,000 | $0.84 | $25.2K | |
| Nov 12, 2025 | Chakma Justin | Executive | Sale | 30,000 | $8.91 | $267.3K | |
| Nov 12, 2025 | Chakma Justin | Executive | Sale | 136,380 | $8.86 | $1.2M | Large |
| Aug 21, 2025 | D. Scott Kathleen | Executive | Sale | 12,500 | $15.00 | $187.5K | |
| Aug 21, 2025 | D. Scott Kathleen | Executive | Option Exercise | 12,500 | $1.50 | $18.8K | |
| Aug 21, 2025 | E. Lowenthal Richard | Executive | Sale | 50,000 | $14.49 | $724.5K | Large |
| Aug 20, 2025 | Tanimoto Sarina | Executive | Sale | 37,656 | $14.09 | $530.6K | Large |
| Aug 19, 2025 | Tanimoto Sarina | Executive | Sale | 12,344 | $14.03 | $173.2K | |
| Jun 27, 2025 | E. Flynn James | Executive | Sale | 370,075 | $18.46 | $6.8M | Large |
| Jun 27, 2025 | E. Flynn James | Executive | Sale | 370,074 | $18.46 | $6.8M | Large |
| Sep 18, 2024 | Karas Eric | Executive | Option Exercise | 10,000 | $1.50 | $15.0K | 10b5-1 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 152 | $76.6M | 59.2% |
Purchase(P) | 11 | $51.3M | 39.6% |
Exercise(M) | 30 | $1.5M | 1.1% |
Gift(G) | 15 | $0 | 0.0% |
Other(J) | 2 | $0 | 0.0% |
Award(A) | 14 | $0 | 0.0% |
Insider activity at ARS Pharmaceuticals, Inc. shows mixed signals across all time. While $51.3M in purchases indicates some executive confidence,$76.6M in sales balances the picture, resulting in a modest net flow of -$25.4M.19 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Capital Management, L.p. Ra, has transacted $36.5M during this period.